A total of 228 patients with multiple myeloma (MM), 166 patients receiving autologous transplantation (124 PBSC and 38 BM) and 66 patients receiving T-cell-depleted allogeneic transplantation were analyzed to compare overall survival (OS), progression-free survival (PFS) and risk of relapse. Patients receiving autologous transplantation had a significantly improved OS (P ¼ 0.006) and PFS (P ¼ 0.002) at 2 years with OS and PFS for autologous transplant 74% and 48%, respectively, compared with 51% and 28% for allogeneic transplantation. By 4 years after transplantation, outcome was similar with OS and PFS for autologous transplantation 41% and 23%, respectively, compared with 39% and 18% for allogeneic transplantation. The 4-year cumulative incidence of nonrelapse mortality was significantly higher in patients receiving allogeneic transplantation (24% vs 13%) (P ¼ 0.004). Relapse was the principle cause of treatment failure for both groups; however, there was a significantly reduced risk of relapse associated with allogeneic transplantation at 4 years: 46% for allograft vs 56% for autograft (P ¼ 0.02). Despite a lower risk of relapse after allogeneic transplantation, autologous transplantation is associated with improved OS and PFS compared with allogeneic transplantation in patients with MM. Strategies focused on reducing nonrelapse mortality in allogeneic transplantation may translate into an improved outcome for patients receiving allogeneic transplantation. Bone Marrow Transplantation (2003) 32, 1145-1151. doi:10.1038/sj.bmt.1704289 Keywords: multiple myeloma; stem cell transplantation; graft-versus-myeloma Multiple myeloma (MM) remains incurable with conventional therapy; therefore, high-dose therapy approaches with either autologous or allogeneic stem cell support have been explored. Although a large randomized trial has demonstrated superior response rates, overall survival (OS) and event-free survival using high-dose therapy with autologous bone marrow transplant (BMT) compared with conventional therapy, disease eventually recurs and relapse remains the principle reason for treatment failure after autologous BMT.
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A total of 228 patients with multiple myeloma (MM), 166 patients receiving autologous transplantation (124 PBSC and 38 BM) and 66 patients receiving T-cell-depleted allogeneic transplantation were analyzed to compare overall survival (OS), progression-free survival (PFS) and risk of relapse. Patients receiving autologous transplantation had a significantly improved OS (P ¼ 0.006) and PFS (P ¼ 0.002) at 2 years with OS and PFS for autologous transplant 74% and 48%, respectively, compared with 51% and 28% for allogeneic transplantation. By 4 years after transplantation, outcome was similar with OS and PFS for autologous transplantation 41% and 23%, respectively, compared with 39% and 18% for allogeneic transplantation. The 4-year cumulative incidence of nonrelapse mortality was significantly higher in patients receiving allogeneic transplantation (24% vs 13%) (P ¼ 0.004). Relapse was the principle cause of treatment failure for both groups; however, there was a significantly reduced risk of relapse associated with allogeneic transplantation at 4 years: 46% for allograft vs 56% for autograft (P ¼ 0.02). Despite a lower risk of relapse after allogeneic transplantation, autologous transplantation is associated with improved OS and PFS compared with allogeneic transplantation in patients with MM. Strategies focused on reducing nonrelapse mortality in allogeneic transplantation may translate into an improved outcome for patients receiving allogeneic transplantation. Bone Marrow Transplantation (2003) 32, 1145-1151. doi:10.1038/sj.bmt.1704289 Keywords: multiple myeloma; stem cell transplantation; graft-versus-myeloma Multiple myeloma (MM) remains incurable with conventional therapy; therefore, high-dose therapy approaches with either autologous or allogeneic stem cell support have been explored. Although a large randomized trial has demonstrated superior response rates, overall survival (OS) and event-free survival using high-dose therapy with autologous bone marrow transplant (BMT) compared with conventional therapy, disease eventually recurs and relapse remains the principle reason for treatment failure after autologous BMT. 1 Allogeneic transplantation has reduced the risk of relapse compared with autologous transplantation due to both the infusion of a tumor-free graft, and the potential for a graft-versus-MM effect mediated by the donor graft. However, allogeneic transplantation in MM is associated with a high treatment-related mortality (TRM), up to 40-50% in some studies, which results in a long-term diseasefree survival in only 15-20% of patients. [2] [3] [4] owing to the recognition of an immune-mediated graft versus MM effect, there is renewed interest in reducing the toxicity of allogeneic transplantation strategies to treat patients with MM.
The potential benefits and toxicity of allogeneic transplantation must be weighed against those of a less toxic autologous transplant. A retrospective case-matched study performed by the European Group for Blood and Marrow Transplantation has reported an inferior outcome for patients receiving allogeneic transplantation, due primarily to increased TRM despite a lower risk of relapse. 5 However, when patients surviving over a year after transplantation were analyzed, thereby discounting the upfront toxicity associated with the transplant, there was a trend toward improved OS and progression-free survival (PFS) in patients receiving allogeneic transplantation.
In this study, we compared the OS, PFS and risk of relapse in 228 patients receiving either autologous or allogeneic transplantation for MM at a single center over an approximately 10 year period. All patients undergoing allogeneic transplantation, received T-cell-depleted bone marrow in an attempt to reduce transplant-related complications. This report also includes patients receiving allogeneic transplantation who received donor lymphocyte infusions (DLI) for the treatment of relapse or as prophylaxis to improve outcome. OS and PFS at 2 years was significantly improved in the autograft recipients compared with allograft recipients. However, by 4 years after transplantation the OS and PFS are similar in autograft and allogeneic recipients due to the higher rate of disease relapse after autologous transplant.
Materials and methods
Patients included 228 adults who underwent either autologous or allogeneic stem cell transplantation at the DanaFarber Cancer Institute and Brigham and Women's Hospital between 1 January 1990 and 1 July 2000. Patients were treated on Institutional Review Board approved protocols after appropriate informed consent.
Patient characteristics are outlined in Table 1 . Patients with HLA-matched sibling donors were recommended to undergo allogeneic transplantation. In total, 162 patients underwent autologous transplantation, 38 patients with bone marrow and 124 patients with peripheral blood stem cells (PBSC). A total of 62 patients received allogeneic T-cell-depleted bone marrow transplants from HLAidentical siblings. All patients had chemotherapy-responsive disease prior to transplantation. The majority of patients had evidence of persistent disease at the time of transplant with only five (3%) patients receiving autologous transplant and four (6%) patients receiving allogeneic transplant in a complete remission at the time of transplantation. The groups were comparable with respect to age (o40 vs 440 years), gender, isotype of disease (IgA vs all others) and stage of disease at diagnosis (stage I-II vs all others). Patients receiving allogeneic transplantation were more heavily pretreated than patients undergoing autologous transplantation (P ¼ 0.05). Transplantation was more often performed in the first year after diagnosis in patients receiving autologous transplantation (57%) than in patients receiving allogeneic transplantation (42%) (P ¼ 0.04). Among those patients alive, the median follow-up is 2.1 years for patients receiving autologous transplantation vs 3.1 years for patients undergoing allogeneic transplantation (P ¼ 0.22).
Conditioning regimens
The conditioning regimens used are outlined in Table 2 . For patients undergoing autologous transplantation, 94 patients (58%) received melphalan and total body irradiation (TBI), 35 (22%) cyclophosphamide and total body irradiation and 33 (20%) busulfan and cyclophosphamide due to prior radiation therapy, which precluded TBI. A total of 62 (91%) patients undergoing allogeneic transplantation received cyclophosphamide and TBI; six (9%) patients were treated with busulfan and cyclophosphamide due to prior radiation therapy, which precluded TBI.
Patients treated with melphalan and TBI received melphalan 70 mg/m 2 /day on two successive days, followed by 1200-1400 cGy TBI administered in 200 cGy fractions. Comparison of auto and allo transplant in myeloma E Alyea et al
Patients treated with cyclophosphamide and TBI received cyclophosphamide 60 mg/kg/day on two successive days, followed by 1400 cGy TBI administered in seven equal 200 cGy fractions administered b.i.d. over 3.5 days. Lung compensation was used to provide uniform radiation dose distribution. All patients receiving TBI were treated on a dedicated facility at 10 cGy/min. Patients treated with busulfan received 16 mg/kg (1 mg/kg q 6 h for a total of 16 doses) and cyclophosphamide as described above.
Stem cell product
Patients receiving autologous transplantation received stem cell products listed in Table 2 . In all, 38 (23%) patients received bone marrow that was purged with monoclonal antibodies to CD10, CD20 and PCA-1 and complement lysis, as previously described; 6, 7 Nine (6%) patients received PBSC products purged in a similar fashion; 14 (9%) patients received unmanipulated PBSC products; 101 (62%) patients received CD34 þ selected PBSC products processed using the CellPro selection device.
All patients undergoing allogeneic transplantation received T-cell-depleted bone marrow from HLA-identical sibling donors. T-cell depletion was performed using anti-CD6 monoclonal antibody and complement lysis, as previously described.
8 CD6 depletion of donor bone marrow was the sole method of GVHD prophylaxis. Marrow was infused via an indwelling catheter the same day it was harvested on day 0.
CD4 þ donor lymphocyte infusion
In all, 24 of 66 (36%) patients who received allogeneic transplantation were treated on a defined protocol combining BMT and CD4 þ DLI. Patients on this protocol were eligible to receive prophylactic CD4 þ DLI 6-9 months after BMT in an effort to induce a graft versus MM effect. 19 Donor lymphocytes were obtained from the BM donor by apheresis using peripheral venous access, followed by CD8 depletion to enrich for CD4 þ DLI as described previously. 9 Of the 24 (58%) patients, 14 enrolled in the protocol received CD4 þ DLI at 6-9 months after transplantation; 11 of these patients received a single infusion of 3 Â 10 7 CD4 þ cells/kg, and three patients received a single infusion of 1 Â 10 7 CD4 þ cells/kg. No immune modulating therapy was given after DLI, and no GVHD prophylaxis was used. Of the 42 patients who had undergone allogeneic bone marrow transplant, 10 patients received CD4 þ DLI for the treatment of relapse.
Supportive care
All patients were treated in HEPA-filtered rooms using standard reverse isolation procedures. Oral prophylactic antibiotics were administered to all patients. Broadspectrum intravenous antibiotics were administered and oral antibiotics were discontinued at the time of development of fever. All blood components were irradiated to prevent transfusion-related GVHD.
Definitions of response
Responses were classified using standard criteria. Immunoelectropheresis and immunofixation were used to evaluate for the presence of serum and/or urine monoclonal immunoglobulin. Marrow examination included staining to demonstrate Ig light-chain restriction. A complete response (CR) was defined by the presence of o5% polyclonal plasma cells in the BM and the absence of a monoclonal protein in serum or urine by immunofixation. A partial response (PR) was the presence of a 450% decrease in the serum and/or urine monoclonal protein and o10% monoclonal plasma cells on BM biopsy. Stable disease was a o50% reduction in paraprotein. Progressive disease was defined as the reappearance of serum and/or urine monoclonal protein for patients in CR, or 425% increase in serum and/or urine monoclonal protein from lowest value observed for patients in PR.
Statistical methods
Patient characteristics were compared between the two groups using Fisher's exact test and the Wilcoxon rank-sum test, as appropriate. 10 PFS, current progression-free survival (CPFS) and OS were estimated using the Kaplan--Meier method and compared univariately using the Wilcoxon test. 11, 12 All time to event end points are measured from the time of marrow infusion. CPFS is defined as the time from infusion to the first relapse, progression or death among those patients who did not receive DLI; and time from infusion to the first relapse, progression or death after DLI among those patients who received DLI. The Wilcoxon test was used instead of the log-rank test because of the earlier differences that were expected. Similarly, the Wilcoxon test was used in the univariate analysis of patient characteristics with PFS, CPFS and OS. To compare the cumulative incidence of relapse between the two groups with nonrelapse mortality as a competing risk, the two-sample test proposed by Gray 13 was used. Owing to the significant difference in follow-up by stem cell source for autologous patients (5.3 years BM vs 1.7 years for PBSC), comparisons of PFS, OS and CPFS by stem cell source was made by comparing the proportion of patients who had not failed at 1 and 2 years using a Fisher's exact test.
The Cox proportional hazards models were used to adjust for potential confounders of OS, PFS and CPFS between the two groups. The covariates considered for inclusion in this model include age (o40 vs X40 years), gender, isotype (IgA vs others), stage at diagnosis (I-II vs III, plasmacytoma) and time from diagnosis to BMT (X1 vs 41 year). The number of prior treatments was not included in the model because of the significant difference in median follow-up (2.7 years for 1 prior regimen vs 4.5 years for 41 prior regimen, P ¼ 0.0006). In addition, subset analyses were done among the autologous and allogeneic patients, separately. The additional covariates included in the model for the allogeneic patients were CMV status of patient-donor and donor gender.
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Results
OS and PFS
Autologous transplantation was associated with improved OS (P ¼ 0.006) and CPFS (P ¼ 0.002), when compared with allogeneic transplantation (Figures 1 and 2) . When assessed at 2 years after transplantation, OS was 74% after autologous transplantation, compared with 51% post allogeneic BMT. Similarly, the 2 year PFS was 48% for patients receiving autologous transplantation, compared with 28% for recipients of allogeneic BMT. However, by 4 years after transplantation OS was similar, 41% for recipients of autologous transplantation vs 39% for allogeneic transplantation; as was PFS, 23% for recipients of autologous transplantation vs 23% for allogeneic transplantation.
Relapse and treatment failure
The causes of treatment failure for patients treated with autologous and allogeneic transplantation are outlined in Table 3 . Relapse was the principle cause of treatment failure for both modalities of transplantation: 71% of patients receiving autologous transplantation and 45% of patients receiving allogeneic transplantation relapsed. However, the 4-year cumulative incidence of nonrelapse mortality was significantly higher in patients receiving allogeneic transplants (24%) than in patients receiving autologous transplantation (13%) (P ¼ 0.004) (Figure 3 ). The incidence of relapse at 2 and 4 years in patients receiving autologous transplantation was 22 and 56%, respectively, compared with 31 and 46%, respectively, for patients receiving allogeneic transplantation. Infectious complications and GVHD were the principle causes of nonrelapse TRM in allogeneic transplant patients, accounting for 24 and 7% of treatment failures, respectively.
PFS and effect of GVM
CD4 þ DLI was administered at the time of relapse to 10 patients: three patients obtained a CR, two patients a PR and five patients demonstrated no evidence of response. One patient who achieved a CR and both patients achieving a PR subsequently progressed. Two patients remain in CR at 7 and 5.5 years after DLI. A total of 14 patients received DLI at 6 months after BMT in a trial combining T-cell-depleted BMT and CD4 þ DLI. In the 14 patients receiving DLI 6 months after transplant, three were in CR and 11 patients had persistent disease at the time of DLI. Of the 11 patients with persistent disease, six patients developed CR and four patients PR post DLI.
Autologous transplant is associated with an improved CPFS compared with allogeneic transplantation despite DLI as salvage therapy. In a competing risk analysis of CPFS (relapse vs nonrelapse mortality), however, autologous patients were found to be at an increased risk for relapse compared to allogeneic patients (P ¼ 0.02) (Figure 4 ). In total, 162 patients received autologous transplantation: 101 patients (62%) received CD34 selected PBSC, 14 (9%) unpurged PBSC and nine (6%) purged PBSC and 38 (23%) patients received purged bone marrow. No significant difference was noted in PFS in recipients of PBSC vs BM at 1 year (76 vs 83%, P ¼ 0.54) or 2 years (44 vs 54%, P ¼ 0.99). OS was also similar between recipients of PBSC and BM at 1 year (83 vs 92%, P ¼ 0.60) and 2 years (71 vs 78%). The effect of conditioning regimen on outcome was also assessed. There was no difference in PFS (P ¼ 0.46) or OS (P ¼ 0.74) in patients receiving either cyclophosphamide/ TBI, cyclophosphamide/busulfan or melphalan/TBI.
Prognostic features associated with outcome
All 228 patients were analyzed for prognostic features that predicted OS and PFS (Table 4 ). A multivariate model was fit which included type of transplant, advanced age, patient gender, isotype, stage of disease and time from diagnosis to BMT 41 year. In the multivariate model, allogeneic transplantation was associated with an increased risk for PFS (1.7, P ¼ 0.004), CPFS (1.5, P ¼ 0.05) and OS (1.7, P ¼ 0.04), when compared with autologous transplantation. Stage III disease at diagnosis was also associated with an increased risk for PFS (1.7, P ¼ 0.01), CPFS (1.5, P ¼ 0.04) and OS (1.7, P ¼ 0.01), compared with earlier stages of disease. Patient age greater than 40 years, patient gender, IgA isotype and time from diagnosis to BMT were not found to be significantly associated with PFS, OS or CPFS. Sufficient data regarding b2-microgobulin level, C reactive protein and cytogenetics were not available to assess their significance.
Prognostic features predicting for OS and PFS were also analyzed separately for 162 patients receiving autologous transplantation and 62 patients receiving allogeneic transplantation. No factor analyzed was predictive for outcome in patients receiving autologous transplantation. Advanced stage disease at the time of diagnosis was significantly associated with a higher risk for PFS (3.3, P ¼ 0.002), CPFS (2.0, P ¼ 0.03) and OS (2.5, P ¼ 0.01) in patients receiving allogeneic transplantation.
Discussion
Despite the potential benefits of infusion of a tumor-free graft and the presence of graft-versus-myeloma effect, highdose therapy with allogeneic transplantation is associated with a significantly inferior PFS and OS than autologous transplantation 2 years after treatment. This inferior outcome is related to a significantly higher incidence of treatment-related complications in patients receiving allogeneic transplantation, compared with patients undergoing autologous transplantation. The relapse rate was significantly higher for patients receiving autologous transplantation, compared with recipients of allogeneic transplantation, demonstrating the impact of a GVM effect. Despite the lower relapse rate with allogeneic transplantation, the increased treatment-related complications resulted in an inferior PFS and OS compared with autologous transplantation.
A prior retrospective comparison of autologous and allogeneic transplantation in patients with MM has demonstrated a similar result. In a case-matched analysis performed by the EBMT comparing 189 MM patients treated with allogeneic transplantation with an equal number of patients treated with autologous transplantation, OS was significantly better after autologous transplantation than after allogeneic transplantation. 5 The main [14] [15] [16] These results suggest that reduction of TRM post allografting may facilitate translation of a lower relapse rate into improved patient outcome.
In the current study, T-cell depletion of allogeneic donor BM was used as GVHD prophylaxis in an attempt to reduce TRM. The TRM noted in this study (24%) compares favorably with that reported in other studies of allogeneic transplantation in MM; nonetheless, the increased frequency of treatment-related complications in allograft recipients compared with autograft patients accounts for inferior results of allografting. The principle treatment-related complications of allogeneic transplantation were infection and GVHD. Possible reasons for the increased treatment-related complications seen in patients with MM include advanced age at the time of transplantation, which is associated with an increased risk of GVHD, and compromised renal function in some patients, which makes the administration of immunosuppressive medications such as cyclosporine difficult. In addition, steroidbased MM treatments used prior to transplantation may increase the risk of infectious complications after transplantation. These transplant-related complications prevent patients from benefiting from the potent GVM effect seen after allogeneic transplantation.
DLI studies have demonstrated direct evidence of a GVM effect; however, the optimal dose of cells to be administered at the time of relapse remains unknown. Studies have suggested that doses 41 Â 10 8 CD3 þ cells/kg are associated with an improved response rate; however, complete responses have been noted even at lower doses. 17, 18 Administration of DLI early after transplantation, while patients are in a minimal disease state, may improve response rates. We have recently reported clinical results using prophylactic CD4 þ DLI given 6 months after T-cell-depleted transplant. 19 Significant responses were seen, with six of 11 patients with persistent disease post transplant achieving CR following DLI. Unfortunately, 42% of patients in this trial were not able to receive DLI due to transplant-related complications. Nonmyeloablative transplant approaches may reduce the complications associated with transplantation, and thereby provide a platform for more patients to benefit from a GVM effect related to allogeneic transplantation, with or without DLI. [20] [21] [22] [23] [24] The durability of GVM is not known. As demonstrated in this study, there is a continuous risk of relapse after allogeneic transplantation. While long-term CRs extending over 6 years have been noted in patients following DLI, relapses after DLI have also occurred in patients achieving CR. Therefore, patients should be monitored closely for evidence of recurrent disease after DLI, and a strategy of retreatment with DLI may be needed to achieve sustained responses.
Relapse of disease remains the principle reason for treatment failure after autologous transplantation. In the current study, no difference in outcome was noted with the use of BM vs PBSC. Efforts to improve the results of autologous transplantation have included purging using monoclonal antibodies directed at antigens expressed on MM cells, CD34 selection of normal PBSCs and increased dose intensity with tandem transplantation. 6, [25] [26] [27] Despite a 3 log reduction in MM burden in the autograft by virtue of CD34 selection, a randomized trial has demonstrated equivalent OS and PFS in recipients of CD34 þ PBSC vs unselected PBSC. 27, 28 Although the GVM effect is significant and results in long-term remissions in some patients, the optimal platform for induction of GVM has yet to be defined. Until the safety, effectiveness and appropriate timing of nonmyeloablative transplantation is further defined in patients with MM, autologous transplantation followed by nonmyleoablative transplantation at the time of progressive disease may be a reasonable treatment plan. Ultimately, identification of the target antigens and effector cells mediating GVM may allow for more targeted, potent and less-toxic alloimmune therapies in the future.
